Abstract: The present invention provides oligonucleotides for use in the treatment of hepatitis B or hepatitis B virus infection in a human patient.

Abstract: The present invention relates to a method for identifying a compound that prevents, ameliorates and/or inhibits a hepatitis virus (HBV) infection, wherein a compound that reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7) is identified as a compound that prevents, ameliorates and/or inhibits a BV infection. The invention also provides for inhibitors of PAPD5 or PAPD7 for use in treating and/or preventing a HBV infection; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of a HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection, and a method for monitoring the therapeutic success during the treatment of a HBV infection.

Abstract: The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of certain antiviral compounds and immune modulator compounds.

Abstract: The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of a therapeutic oligonucleotide targeting HBV and a TLR7 agonist for use in the treatment of a chronic hepatitis B patient.

Abstract: The present invention relates to nucleic acid molecules that are complementary to both PAP associated domain containing 5 (PAPD5) and PAP associated domain containing 7 (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The invention also provides for PAPD5 and PAPD7 specific nucleic acid molecules for use in treating and/or preventing a HBV infection, in particular a chronic HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection.

Abstract: A method for identifying a compound that prevents, ameliorates and/or inhibits a hepatitis B virus (HBV) infection is provided, wherein a compound that reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7) is identified as a compound that prevents, ameliorates and/or inhibits a HBV infection. Inhibitors of PAPD5 or PAPD7 are provided for use in treating and/or preventing a HBV infection; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of a HBV infection.

Abstract: The present invention relates to nucleic acid molecules that are complementary to both PAP associated domain containing 5 (PAPD5) and PAP associated domain containing 7 (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The invention also provides for PAPD5 and PAPD7 specific nucleic acid molecules for use in treating and/or preventing a HBV infection, in particular a chronic HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection.

Abstract: The present invention relates to a method for identifying a compound that prevents, ameliorates and/or inhibits hepatitis B virus (HBV) infections. The compound (i) reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7); and/or (ii) binds to PAPD5 and/or PAPD7 and inhibits 5 propagation of HBV; and is identified as a compound that prevents, ameliorates and/or inhibits HBV infections. An inhibitor of PAPD5 and/or PAPD7 for use in treating and/or preventing HBV infections; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of HBV infections is also provided. The present invention includes a 10-pharmaceutical composition for use in treatment and/or prevention of HBV infections, and a method for monitoring therapeutic success during treatment of HBV infections.

Abstract: The present invention relates to a method for identifying a compound that prevents, ameliorates and/or inhibits a hepatitis B virus (HBV) infection, wherein a compound that (i) reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7); and/or (ii) binds to PAPD5 and/or PAPD7 and inhibits 5 propagation of HBV; is identified as a compound that prevents, ameliorates and/or inhibits a HBV infection. The invention also provides for an inhibitor of PAPD5 and/or PAPD7 for use in treating and/or preventing a HBV infection; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of a HBV infection. Also comprised in the present invention is a 10 pharmaceutical composition for use in the treatment and/or prevention of a HBV infection, and a method for monitoring the therapeutic success during the treatment of a HBV infection.

Abstract: The present invention relates to nucleic acid molecules that are complementary to both PAP associated domain containing 5 (PAPD5) and PAP associated domain containing 7 (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The invention also provides for PAPD5 and PAPD7 specific nucleic acid molecules for use in treating and/or preventing a HBV infection, in particular a chronic HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection.

Abstract: The present invention relates to nucleic acid molecules that are complementary to both PAP associated domain containing 5 (PAPD5) and PAP associated domain containing 7 (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The invention also provides for PAPD5 and PAPD7 specific nucleic acid molecules for use in treating and/or preventing a HBV infection, in particular a chronic HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection.

Abstract: The present invention relates to a method for identifying a compound that prevents, ameliorates and/or inhibits a hepatitis B virus (HBV) infection, wherein a compound that reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7) is identified as a compound that prevents, ameliorates and/or inhibits a HBV infection. The invention also provides for inhibitors of PAPD5 or PAPD7 for use in treating and/or preventing a HBV infection; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of a HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection, and a method for monitoring the therapeutic success during the treatment of a HBV infection.

Abstract: The present invention relates to a method for identifying a compound that prevents, ameliorates and/or inhibits a hepatitis B virus (HBV) infection, wherein a compound that (i) reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7); and/or (ii) binds to PAPD5 and/or PAPD7 and inhibits 5 propagation of HBV; is identified as a compound that prevents, ameliorates and/or inhibits a HBV infection. The invention also provides for an inhibitor of PAPD5 and/or PAPD7 for use in treating and/or preventing a HBV infection; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of a HBV infection. Also comprised in the present invention is a 10 pharmaceutical composition for use in the treatment and/or prevention of a HBV infection, and a method for monitoring the therapeutic success during the treatment of a HBV infection.

Abstract: The present invention relates to nucleic acid molecules that are complementary to both PAP associated domain containing 5 (PAPD5) and PAP associated domain containing 7 (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The invention also provides for PAPD5 and PAPD7 specific nucleic acid molecules for use in treating and/or preventing a HBV infection, in particular a chronic HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection.

Abstract: Glazings comprising first and second channel-section glazing elements are described. The first and second channel-section glazing elements are arranged to define a cavity in which is located an inner glazing element comprising a glass glazing element, in particular a soda-lime-silica glass sheet, channel-section glazing element or sheet of rolled glass having at least one fire polished edge. The inner glazing element divides the cavity into at least two spaces to improve the thermal and/or noise performance of the glazing. By using low emissivity coatings on one or more major surfaces of one or more of the glazing elements, the thermal performance may be further improved. Mechanical performance may be modified by the particular type of inner glazing element used. It is possible to retrofit existing glazings to improve the thermal and/or noise performance thereof.

Abstract: Glazings comprising first and second channel-section glazing elements are described. The first and second channel-section glazing elements are arranged to define a cavity in which is located an inner glazing element comprising a glass glazing element, in particular a soda-lime-silica glass sheet, channel-section glazing element or sheet of rolled glass having at least one fire polished edge. The inner glazing element divides the cavity into at least two spaces to improve the thermal and/or noise performance of the glazing. By using low emissivity coatings on one or more major surfaces of one or more of the glazing elements, the thermal performance may be further improved. Mechanical performance may be modified by the particular type of inner glazing element used. It is possible to retrofit existing glazings to improve the thermal and/or noise performance thereof.

Abstract: The invention relates to a coaxial smoking article, particularly a coaxial cigarette, comprising a coaxial rod of smokable material, which rod has an inner segment (1) of smokable material surrounded by a covering (2), around which covering is an outer segment (3) of combustible or thermally destructible/decomposable material, which outer segment is also surrounded by a covering (4). The combustible or thermally destructible/decomposable material of the outer segment contains no or only a very small proportion of spot-forming substances. Further, the coverings of the inner and outer segments are such that spot-forming substances in the inner segment are essentially unable to reach the outside of the covering. Hence, a cigarette having reduced potential for the production of spotting is so formed.

Abstract: A private communication system and an allocated, private communication terminal equipment that is not directly connectable, i.e. that is "external", has a respective terminal equipment emulation unit allocated to it. This terminal equipment emulation unit pair are connectable to one another at least via a public dialed communication network, where the connection of at least one message path and of an additional signaling path is controlled via the public dialed communication network and the switching of the paths suited to the terminal equipment emulation unit pair is checked. With the assistance of the terminal equipment emulation unit pair, isolated or external communication terminal equipment can be connected without diminishing the scope of performance features of private communication networks. Misconnections and false signalings are avoided by checking the connection suited to the terminal equipment emulation unit pair with the assistance of a specific check procedure.

Abstract: Communication system for multi-service communication terminal equipment in local networks. A local network in which communication terminal equipment (KE; "multi media" communication terminal equipment) additionally having narrow-band and telephone services (SB, FE) are provided in addition to network-specific services is connected via an interworking unit (APE) to subscriber line interfaces (TAS) of a communication system (KA) having narrow band and telephone communication functions (SB, FE). As a result of the insertion of an interworking unit (APE) equipped with subscriber equipment (TLE), a matching unit (AE) and an access means (LANZ) onto the local network (LAN), the functions of both networks (narrow band and telephone network and local network LAN) are preserved largely unmodified and a maximally possible modularity and flexibility given the least additional outlay are achieved in structuring and formatting communication systems with "multi media" communication terminal equipment.